Evidence map›Paper›PMID 36653422›Full record

ArticleScientific reports2023

A cross-sectional study of inflammatory markers as determinants of circulating kynurenines in the Lung Cancer Cohort Consortium.

Øivind Midttun, Arve Ulvik, Klaus Meyer, Hana Zahed, Graham G Giles, Jonas Manjer, Malte Sandsveden, Arnulf Langhammer, Elin Pettersen Sørgjerd, Annelie F Behndig and 25 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 6 countries.

Øivind MidttunBevital AS, Laboratory Building, Jonas Lies Veg 87, 5021, Bergen, Norway. oivind.midttun@bevital.no.
Arve UlvikBevital AS, Laboratory Building, Jonas Lies Veg 87, 5021, Bergen, Norway.
Klaus MeyerBevital AS, Laboratory Building, Jonas Lies Veg 87, 5021, Bergen, Norway.
Hana ZahedGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.
Jonas ManjerDepartment of Surgery, Skane University Hospital, Malmö, Sweden.
Malte SandsvedenDepartment of Clinical Sciences Malmo, Lund University, Malmö, Sweden.
Arnulf LanghammerDepartment of Public Health and Nursing, Hunt Research Centre, Norwegian University of Science and Technology, Levanger, Norway.
Elin Pettersen SørgjerdDepartment of Public Health and Nursing, Hunt Research Centre, Norwegian University of Science and Technology, Levanger, Norway.
Annelie F BehndigDepartment of Public Health and Clinical Medicine, Umea University, Umeå, Sweden.
Mikael JohanssonDepartment of Radiation Sciences, Oncology, Umea University, Umeå, Sweden.
Neal D FreedmanMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Wen-Yi HuangMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Chu ChenPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.
Ross PrenticePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.
Victoria L StevensAmerican Cancer Society, Atlanta, USA.
Ying WangAmerican Cancer Society, Atlanta, USA.
Loïc Le MarchandUniversity of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, USA.
Stephanie J WeinsteinMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Qiuyin CaiVanderbilt University Medical Center, Nashville, USA.
Alan A ArslanDepartment of Obstetrics and Gynecology, NYU Langone Health, New York, NY, USA.
Yu ChenDepartment of Population Health, NYU Langone Health, New York, NY, USA.
Xiao-Ou ShuDepartment of Population Health, NYU Langone Health, New York, NY, USA.
Wei ZhengDepartment of Population Health, NYU Langone Health, New York, NY, USA.
Jian-Min YuanUniversity of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, USA.
Woon-Puay KohHealthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Kala VisvanathanJohns Hopkins Institute for Clinical and Translational Research, Baltimore, USA.
Howard D SessoBrigham and Women's Hospital, Harvard Medical School, Boston, USA.
Xuehong ZhangBrigham and Women's Hospital, Harvard Medical School, Boston, USA.
J Michael GazianoBrigham and Women's Hospital, Boston, USA.
Anouar FanidiUniversité Claude Bernard Lyon 1, Lyon, France.
Hilary A RobbinsGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Paul BrennanGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Mattias JohanssonGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Per M UelandBevital AS, Laboratory Building, Jonas Lies Veg 87, 5021, Bergen, Norway.
Bevital (Norway) · NONYU Langone Health · USCentre international de recherche sur le cancer · FRUmeå University · SEAmerican Cancer Society · USDivision of Cancer Epidemiology and GeneticsFred Hutch Cancer Center · USLund University · SEBrigham and Women's Hospital · USCancer Center of Hawaii · USCancer Council Victoria · AUHarvard University · USLevanger Hospital · NONational Cancer Institute · USNational University of Singapore · SGSt Olav's University Hospital · NOUniversité Claude Bernard Lyon 1 · FRUPMC Hillman Cancer Center · USVA Boston Healthcare System · USVanderbilt University Medical Center · US

Funding

Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
RESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, Rayjean J. Hung · 2017 to 2026
$23.7M
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) StudyZIACP010195 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2009 to 2025
$22.5M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Prospective studies of cancer etiology and prevention in Shanghai and SingaporeR01CA144034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2010 to 2014
$7.0M
Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
THE SINGAPORE COHORT STUDY OF DIET AND CANCERR01CA080205 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YUAN, JIAN-MIN · 1999 to 2009
$5.3M
Shanghai Men's Health StudyUM1CA173640 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHU, XIAO-OU · 2013 to 2017
$4.9M
Cancer epidemiology cohorts in Shanghai and Singapore UM1CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2014 to 2018
$4.3M
CDC HHS NU58DP006333NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA080205NCI NIH HHS R01 CA144034NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA182934NCI NIH HHS U19 CA203654NCI NIH HHS UM1 CA173640NCI NIH HHS UM1 CA182876NCI NIH HHS UM1 CA182910NCI NIH HHS UM1 CA186107NIEHS NIH HHS P30 ES000260NIH HHS HHSN268201600001CNIH HHS HHSN268201600002CNIH HHS HHSN268201600003CNIH HHS HHSN268201600004CNIH HHS HHSN268201600018CNIH HHS R01CA144034NIH HHS U01 CA164973NIH HHS UM1CA182876Wellcome Trust 209057World Health Organization 001
6 · The paper itself

Abstract

Circulating concentrations of metabolites (collectively called kynurenines) in the kynurenine pathway of tryptophan metabolism increase during inflammation, particularly in response to interferon-gamma (IFN-γ). Neopterin and the kynurenine/tryptophan ratio (KTR) are IFN-γ induced inflammatory markers, and together with C-reactive protein (CRP) and kynurenines they are associated with various diseases, but comprehensive data on the strength of associations of inflammatory markers with circulating concentrations of kynurenines are lacking. We measured circulating concentrations of neopterin, CRP, tryptophan and seven kynurenines in 5314 controls from 20 cohorts in the Lung Cancer Cohort Consortium (LC3). The associations of neopterin, KTR and CRP with kynurenines were investigated using regression models. In mixed models, one standard deviation (SD) higher KTR was associated with a 0.46 SD higher quinolinic acid (QA), and 0.31 SD higher 3-hydroxykynurenine (HK). One SD higher neopterin was associated with 0.48, 0.44, 0.36 and 0.28 SD higher KTR, QA, kynurenine and HK, respectively. KTR and neopterin respectively explained 24.1% and 16.7% of the variation in QA, and 11.4% and 7.5% of HK. CRP was only weakly associated with kynurenines in regression models. In summary, QA was the metabolite that was most strongly associated with the inflammatory markers. In general, the inflammatory markers were most strongly related to metabolites located along the tryptophan-NAD axis, which may support suggestions of increased production of NAD from tryptophan during inflammation.

Indexed as

KynurenineLung NeoplasmsBiomarkersC-Reactive ProteinCross-Sectional StudiesHumansInflammationInterferon-gammaNADNeopterinTryptophanBiomarkersC-Reactive ProteinInterferon-gammaKynurenineNADNeopterinTryptophan

Identifiers

PMID36653422
PMCPMC9849351
OpenAlexW4317254634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.